Factor VII

Factor VII is a protein in your blood that helps it clot. It's part of the body's natural clotting system. It's important for stopping bleeding when you get a cut. It's a stable protein, meaning it doesn't break down easily.

Brand names:Proconvertin, Stable Factor
Medication

What people taking Factor VII report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Factor VII

What It's For

Factor VII is one of the proteins the blood needs to form a clot. As a medicine, it is given in a manufactured, already-activated form called recombinant factor VIIa (rFVIIa). It is used to control bleeding in a small group of rare bleeding disorders where standard treatments do not work or are not available. In the US there are two brands with different approved uses. NovoSeven RT treats bleeding episodes and helps prevent bleeding during surgery in adults and children who have hemophilia A or B with inhibitors, an inherited shortage of factor VII (congenital factor VII deficiency), or Glanzmann's thrombasthenia (an inherited platelet disorder) when platelet transfusions no longer work. It is also approved for adults with acquired hemophilia, a condition in which the immune system attacks the body's own clotting factor. Sevenfact is approved only to treat bleeding episodes in people 12 and older with hemophilia A or B with inhibitors, and it is not meant for factor VII deficiency. An inhibitor is an antibody the immune system makes against the factor VIII or factor IX that people with hemophilia normally infuse, which stops that treatment from working. Factor VIIa is called a bypassing agent because it helps the blood clot by a route that does not need factor VIII or IX. Hospitals have also used factor VIIa off-label, outside its approved uses, for heavy bleeding after injury, surgery or bleeding in the brain in people without a bleeding disorder. Reviews of controlled trials have not shown that this saves lives, and it raises the risk of clots in arteries, so that use is generally discouraged outside research.

How It Works

When a blood vessel is injured, a protein called tissue factor is exposed at the site. Factor VIIa binds to tissue factor and switches on the next clotting proteins in the chain, which leads to a burst of thrombin, the enzyme that turns the blood protein fibrinogen into strands of fibrin. Those strands knit platelets into a firm plug that seals the wound. In hemophilia, this chain normally stalls because factor VIII or IX is missing. Giving factor VIIa in high doses pushes thrombin production forward anyway, partly on the surface of activated platelets at the injury, so a clot can form without the missing factor. In factor VII deficiency, it simply replaces the protein the body lacks, which is why much lower doses are used for that condition. Because it adds clotting power to the blood rather than only replacing what is missing, it can also contribute to unwanted clots, which is the main safety concern.

Dosage & Administration

Factor VIIa comes as a powder that is mixed with the liquid supplied in the package and injected into a vein. The dose is based on body weight and on the reason for treatment, and people with factor VII deficiency need much smaller doses than people with hemophilia and inhibitors. It requires frequent infusions: a bleed often needs repeated doses every few hours until the bleeding stops, and surgery needs a planned schedule before, during and after the operation. Treatment works best when it starts as soon as a bleed begins. People with hemophilia and inhibitors usually have a written plan from their hemophilia treatment center that says when and how much to infuse, and some are taught to prepare and infuse doses themselves using the product's instructions for use. Once mixed, the solution must be used within a few hours (3 hours for NovoSeven RT, 4 for Sevenfact) and should not be combined with other infusion fluids. Standard blood clotting tests do not reliably show whether the dose is working, so the care team judges response mainly by whether the bleeding stops.

Side Effects

Most infusions cause no noticeable problems. Reported side effects include fever, headache, dizziness, and discomfort or bruising where the needle went in. The most important risk, highlighted in a boxed warning on both brands, is serious blood clots in arteries or veins. These can cause a heart attack, stroke or a clot in the lungs or legs. In trials, clots were uncommon in people with inherited hemophilia but occurred in about 4% of people treated for acquired hemophilia. Call 911 for new chest pain, shortness of breath, sudden numbness or weakness, or confusion or trouble speaking after an infusion. New swelling and pain in an arm, leg or the abdomen also needs medical help right away. Allergic reactions, including anaphylaxis, can occur. If hives or itching appear during an infusion, stop the infusion and contact the care team right away. Call 911 for chest tightness, wheezing, difficulty breathing, swelling of the mouth or throat, or fainting.

Interactions & Warnings

The main concern with other treatments is stacking clotting medicines. Factor VIIa should not be used at the same time as activated prothrombin complex concentrate (aPCC, sold as FEIBA), the other main bypassing agent, and it should not be given together with factor XIII concentrate (a clotting-factor replacement for people who lack factor XIII). The National Hemophilia Foundation also advises against combining bypassing agents with tranexamic acid or aminocaproic acid (Amicar), pills that keep clots from breaking down, unless the hematologist has planned it. People using emicizumab (Hemlibra), an injection that prevents bleeds in hemophilia A, should treat breakthrough bleeds only as their hemophilia team directs. Factor VIIa is usually the bypassing agent chosen in that situation, because aPCC given with emicizumab has caused serious clots and kidney-damaging small-vessel clotting. The clot risk is higher in older adults and in people with heart disease, narrowed arteries, a past stroke or blood clot, a crush injury or a serious bloodstream infection. Sevenfact must not be used by anyone allergic to rabbits or rabbit proteins, and people with an allergy to cow's milk protein (casein) may be more likely to react to it. NovoSeven RT may be more likely to cause a reaction in people allergic to mouse, hamster or cow proteins. There is little information on use during pregnancy, so anyone pregnant or planning pregnancy should discuss it with their hematologist.

What to Expect

Treating a bleed often takes several doses over hours, and sometimes longer. If bleeding keeps going despite the planned doses, contact the hemophilia team right away, since the dose, the timing or the type of bypassing agent may need to change. Response varies from person to person and there is no standard lab test to predict it, so people with inhibitors often learn over time which bypassing agent and schedule work best for them. Factor VIIa treats bleeds rather than preventing them over the long term. Some people with hemophilia A and inhibitors now use a preventive treatment such as emicizumab and keep a bypassing agent for breakthrough bleeds. People with factor VII deficiency are checked with blood tests before and after treatment, because some develop antibodies against factor VII that make it less effective. Care is usually coordinated through a specialized hemophilia treatment center, and the cost of bypassing agents is high, so insurance planning is often part of treatment.

Questions to Ask Your Doctor

  1. 1.Why is factor VIIa the right bleeding treatment for me rather than aPCC or another option?
  2. 2.What should my written bleed plan say about when to infuse, how many doses to give and when to call you?
  3. 3.How will we know whether the treatment is working, and what happens if a bleed does not stop?
  4. 4.Which of my other medicines, such as tranexamic acid or emicizumab, need to be adjusted when I use it?
  5. 5.Given my age and health, how high is my risk of a blood clot, and what signs should I watch for?

Last reviewed • Oct 2026

Educational content, not medical advice.